<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656226</url>
  </required_header>
  <id_info>
    <org_study_id>ISD-FPT-01-2012</org_study_id>
    <nct_id>NCT01656226</nct_id>
  </id_info>
  <brief_title>Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis</brief_title>
  <official_title>A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISDIN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISDIN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of Eryfotona
      AK-NMSC® topical application vs Sunscreen on cancerization field of actinic keratosis
      patients after 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with partial clearance of AK lesions</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clearance and improvement of AK lesions</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of AK lesions in the treated area (including all lesions present at baseline as well as subclinical lesions which appeared during therapy)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with improvement (clinical and dermoscopic assessment) of the target area as for the erythema, scaling, pigmentation and follicular plugs</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with changes in the Investigator Global Improvement Index</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with changes in Baseline Severity Index (BSI)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with improvement in the target AK lesion by using RCM score.</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with improvement in the &quot;cancerization filed&quot; by RCM score</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period Validation of a new RCM score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients compliant to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients which report satisfaction to local tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups over time and at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with AEs and local AEs (skin reactions)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups over time and at the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients which report satisfaction to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between treatment groups at the end of the treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Eryfotona AK-NMSC® cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunscreen SPF 50+</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eryfotona AK-NMSC® cream</intervention_name>
    <description>Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.</description>
    <arm_group_label>Eryfotona AK-NMSC® cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunscreen SPF 50+</intervention_name>
    <description>Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.</description>
    <arm_group_label>Sunscreen SPF 50+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Current diagnosis of AK, with ≥4 lesions located in the same anatomical district
             (within a contiguous 50 cm2 area on the face, bold scalp or forehead);

          2. Female or male &gt;18 years of age;

          3. Skin type I or II according to Fitzpatrick;

          4. Patient has confirmed his/her willingness to participate in this study;.

        Exclusion Criteria:

          1. Topical drug therapy for AK within the past 3 months or for photoaging in the last 6
             months, or had lesion-directed therapy within 2 cm2 of the selected AK area during the
             previous month;

          2. Suitable for surgical, photodynamic or any other topical treatment in the next 6
             months;

          3. Subjects who suffer/ had suffered from skin cancer or show an early stage of skin
             cancer or have a genetic predisposition for skin cancer;

          4. Other skin disease that requires treatment with other medications in the treatment
             area or in the distance of 3 cm;

          5. Immunosuppression or current treatment for cancer;

          6. Clinically unstable medical condition;

          7. High risk group for HIV infection or presentation of other infectious diseases

          8. Presentation of contact allergies or allergies to compounds of the test substances;

          9. Smoker (more than forty cigarettes per day) or heavy drinker (more than three standard
             drinks per day);

         10. Psychiatric disease that may interfere with follow up of study procedures;

         11. Participation in other clinical trials up to 30 days prior to day 1 of the study

         12. Prior treatment with study medication in the area to be treated;

         13. Considered by the investigator, for any other reason, to be an unsuitable candidate
             for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Giuseppe Argenziano, , MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Unit, Medical Department /Arcispedale Santa Maria Nuova /Reggio Emilia, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Unit, Medical Department Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>AK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

